Literature DB >> 14617001

Progenitor cell involvement is predictive of response to induction chemotherapy in paediatric acute myeloid leukaemia.

Donna L Johnston1, Soheil Meshinchi, Kent E Opheim, Maria G Pallavicini, James Feusner, William G Woods, Beverly J Lange, Jerald P Radich, Irwin D Bernstein.   

Abstract

In acute myeloid leukaemia (AML), involvement of early progenitor cells may predict poor response to induction chemotherapy. We evaluated the involvement of early progenitor cells in two AML subtypes with a favourable prognosis [t(8;21) and t(15;17)], and a subtype with poor prognosis (monosomy 7). CD34+CD33- cells were isolated by fluorescence-activated cell sorting, grown in liquid medium followed by culture in semi-solid medium, and the colonies that were formed were analysed for the identifiable genetic markers. Two of 136 colonies from six t(8;21) AML patients expressed the AML1-ETO transcript, and all six patients achieved remission after induction. None of 192 colonies from five t(15;17) AML patients expressed the RARalpha-PML transcript and all achieved remission. In contrast, in three of 10 cases of monosomy 7 AML, colonies were positive for monosomy 7, and all three patients failed to enter remission. However, five of six evaluable patients with colonies negative for monosomy 7 entered remission. These data support the hypothesis that leukaemic involvement of early progenitor cells affects the response to induction chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14617001     DOI: 10.1046/j.1365-2141.2003.04633.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

Review 1.  Topics in pediatric leukemia--hematopoietic stem cell transplantation.

Authors:  Theodore B Moore; Kathleen M Sakamoto
Journal:  MedGenMed       Date:  2005-03-29

2.  Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML.

Authors:  Jessica A Pollard; Todd A Alonzo; Michael Loken; Robert B Gerbing; Phoenix A Ho; Irwin D Bernstein; Susana C Raimondi; Betsy Hirsch; Janet Franklin; Roland B Walter; Alan Gamis; Soheil Meshinchi
Journal:  Blood       Date:  2012-02-29       Impact factor: 22.113

3.  FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia.

Authors:  Jessica A Pollard; Todd A Alonzo; Robert B Gerbing; William G Woods; Beverly J Lange; David A Sweetser; Jerald P Radich; Irwin D Bernstein; Soheil Meshinchi
Journal:  Blood       Date:  2006-06-29       Impact factor: 22.113

Review 4.  Children's Oncology Group's 2013 blueprint for research: acute myeloid leukemia.

Authors:  Alan S Gamis; Todd A Alonzo; John P Perentesis; Soheil Meshinchi
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

Review 5.  Targeting stem cells-clinical implications for cancer therapy.

Authors:  Lan Chun Tu; Greg Foltz; Edward Lin; Leroy Hood; Qiang Tian
Journal:  Curr Stem Cell Res Ther       Date:  2009-05       Impact factor: 3.828

6.  Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemia.

Authors:  R B Walter; G S Laszlo; J M Lionberger; J A Pollard; K H Harrington; C J Gudgeon; M Othus; S Rafii; S Meshinchi; F R Appelbaum; I D Bernstein
Journal:  Leukemia       Date:  2014-03-18       Impact factor: 11.528

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.